ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Asso...
Data suggest efficacy over standard of care for the treatment of psoriatic arthritisIzokibep was well-tolerated, having a safety profile consisten...
Source: businessinsider.com